

Contents

xI Preface

Ring, J.; Darsow, U.; Behrendt, H. (Munich)

Allergy and Environment: Determinants of Allergy Development

1 Allergy in Evolution

Platts-Mills, T.A.E. (Charlottesville, Va.)

- 1 Abstract
- 1 Evolution of Protein Structures
- 3 'Evolution' of Allergic Diseases: 1870–2000
- 4 Conclusions
- 5 Acknowledgement
- 5 References

7 Climate Change, Environment and Allergy

Behrendt, H.; Ring, J. (Munich)

- 7 Abstract
- 7 Environment and Allergy
- 8 Environmental Pollution
- 9 Western Lifestyle
- 9 Climate Change
- 10 Climate Change Effects upon Pollen
 - 11 More Pollen
 - 11 New Pollen
 - 11 Altered Pollen
 - 12 Other Allergens
- 12 Conclusion
- 12 Acknowledgement
- 12 References

15 The Hygiene Hypothesis Does Not Apply to Atopic Eczema in Childhood

Cramer, C.; Link, E. (Düsseldorf); Koletzko, S. (Munich); Lehmann, I. (Leipzig); Heinrich, J.; Wichmann, H.-E. (Neuherberg); Bauer, C.-P. (Munich); v. Berg, A.; Berdel, D. (Wesel); Herbarth, O. (Leipzig); Schaaf, B. (Bad Honnef); Borte, M. (Leipzig); Behrendt, H. (Munich); Krämer, U. (Düsseldorf)

- 15 Abstract
- 16 Eczema in East and West Germany
- 17 Eczema and Day Care Center Attendance
- 19 Eczema, Older Siblings and *FLG* Mutations
- 21 Conclusion

22	Acknowledgement
22	References

24 Molecular Genetics of Atopic Eczema

Ring, J. (Munich); Möhrenschrager, M. (Davos); Weidinger, S. (Kiel)

24	Abstract
25	Classical Genetics
25	Linkage Studies
25	Genes of Skin Barrier Function
26	Genes Involved in IgE-Mediated Hypersensitivity
27	Genes with Unknown Function
27	Conclusions
27	Acknowledgement
28	References

Pathogenesis of the Deviated Immune Response

30 Mechanisms of Immune Tolerance to Allergens

Fujita, H. (Davos/Yokohama); Meyer, N.; Akdis, M.; Akdis, C.A. (Davos)

30	Abstract
31	Pathogenesis of Allergic Diseases
32	B Regulatory Cells
33	Mechanisms of Allergen-Specific Immunotherapy
33	Role of T Cells
34	Role of Allergen-Specific IgG4
35	Regulation of Basophils, Eosinophils and Mast Cells
35	Clinical Use
36	Conclusions
36	Acknowledgements
37	References

39 Th17 and Th22 in Skin Allergy

Cavani, A. (Rome); Pennino, D.; Eyerich, K. (Munich)

39	Abstract
40	Th17 in Atopic Dermatitis
41	Th22 in Atopic Dermatitis
42	Conclusions
43	References

45 IL-25 Induces Both Inflammation and Skin Barrier Dysfunction in Atopic Dermatitis

Deleuran, M.; Hvid, M. (Aarhus); Kemp, K.; Christensen, G.B. (Ballerup); Deleuran, B.; Vestergaard, C. (Aarhus)

45	Abstract
47	Conclusion and Perspectives
48	References

50 Angiogenesis, Lymphangiogenesis and Atopic Dermatitis

Genovese, A.; Detoraki, A.; Granata, F.; Galdiero, M.R.; Spadaro, G.; Marone, G. (Naples)

50	Abstract
51	Proangiogenic Factors
53	Angiogenic Factors in Atopic Dermatitis
54	Cellular Sources of Angiogenic and Lymphangiogenic Factors in Atopic Dermatitis
56	Angiogenesis and Lymphangiogenesis in Experimental Models of Atopic Dermatitis

- 56 Conclusions
- 57 References

61 What Can Dogs Bring to Atopic Dermatitis Research?

Olivry, T. (Raleigh, N.C.)

- 61 Abstract
- 62 Canine Atopic Dermatitis Is a Common Spontaneous Animal Heritable Skin Disease
- 63 Dogs and Humans with Atopic Dermatitis Exhibit the Same Hypersensitivity Patterns
- 63 Canine and Human Atopic Dermatitis Are Phenotypically Similar
- 64 Canine and Human Atopic Dermatitis Have Similar Treatment Outcome
- 66 Canine and Human Atopic Dermatitis Have Similar Pathogenesis
- 67 Skin Lesions of Canine (and Human) Atopic Dermatitis Can Be Modeled Experimentally
 - 67 Intradermal Challenges with Allergens or Anti-IgE Antibodies
 - 68 Epicutaneous Allergen Challenges of Sensitized Dogs
 - 68 Environmental and Systemic Allergen Challenges of Sensitized Dogs
- 69 Conclusions
- 69 References

73 Can Microbial Superantigens Influence Atopic Dermatitis Flares?

Alomar, A. (Barcelona)

- 73 Abstract
- 74 Effects of *Malassezia* on Immune Response
- 75 Conclusion
- 75 References
- 76 Further Reading

77 Inflammation-Induced Alterations in the Skin Barrier Function: Implications in Atopic Dermatitis

Vestergaard, C.; Hvid, M.; Johansen, C. (Aarhus); Kemp, K. (Ballerup); Deleuran, B.; Deleuran, M. (Aarhus)

- 77 Abstract
- 79 References

Clinical Aspects

81 Itch and Eczema

Darsow, U.; Pfab, F.; Valet, M.; Tölle, T.R.; Ring, J. (Munich)

- 81 Abstract
- 81 Pathophysiology
- 82 Itch Questionnaires in Atopic Eczema
- 83 Processing of the Itch Sensation in the Human Brain
 - 83 Volunteer Studies
 - 84 Patient Studies
- 85 Therapy of Itch in Eczema
- 87 References

89 Eczema Herpeticum

Wollenberg, A. (Munich)

- 89 Abstract
- 89 History and Epidemiology
- 90 Diagnostic Procedures
- 90 Pathogenesis of Eczema Herpeticum
- 91 Therapy of Eczema Herpeticum
- 91 Antiviral Chemotherapy of Eczema Herpeticum

- 92 Topical Treatment of Eczema Herpeticum
- 93 Ophthalmic Therapy
- 93 IFN Therapy for Eczema Herpeticum
- 93 Outlook
- 94 References

96 **Bone Mineral Density in Patients with Atopic Dermatitis**

Haack, I.; van Velsen, S.; de Bruin-Weller, M.; Bruijnzeel-Koomen, C. (Utrecht)

- 96 Abstract
- 98 Conclusions
- 99 References

100 **Immunosuppressive Effect of Prolactin-Induced Protein**

Sugiura, S. (Otsu); Fujimiya, M. (Sapporo); Ebise, H. (Osaka); Miyahira, Y. (Otsu); Kato, I. (Kanazawa); Sugiura, Y. (Tokyo); Kimura, T. (Osaka); Uehara, M. (Yasu); Sato, H. (Otsu); Sugiura, H. (Otsu/Kusatsu)

- 100 Abstract
- 101 Materials and Methods
 - 101 Animals
 - 101 Induction of Oxazolone-Induced Contact Sensitivity
 - 101 Immunohistological Study of the Ear with Anti-Prolactin-Induced Protein Antibody in Oxazolone Challenged Mice
 - 101 Construction of Mouse Prolactin-Induced Protein Peptide
 - 101 Animals and Induction of Oxazolone-Induced Contact Sensitivity
 - 102 Induction of an Immunomodulatory Effect by Prolactin-Induced Protein Peptide
 - 102 Measurement of Ear Thickness and Tissue Sample Collections
 - 102 Histology and Immunohistochemistry of Ears on Mice Treated with Oxazolone and Prolactin-Induced Protein Peptide
 - 103 Statistical Analyses
- 103 Results
 - 103 Expression of Prolactin-Induced Protein in Skin Lesions in a Mouse Chronic Allergic Contact Dermatitis Model
 - 103 Immunosuppressive Effect of Prolactin-Induced Protein Peptide in a Mouse Chronic Allergic Contact Dermatitis Model
- 104 Local Inhibitory Effect of Prolactin-Induced Protein Peptide Observed by Histopathology
- 105 Discussion
- 107 References

Therapy and Management

108 **Is Food Allergy Testing Reliable in Pediatric Atopic Dermatitis? A Population-Based Study**

Keck, L.E.; Simpson, E.L.; Berry, T.M.; Hanifin, J.M. (Portland, Oreg.)

- 108 Abstract
- 109 Methods
- 109 Results
- 110 Discussion
- 111 Acknowledgement
- 111 References

113 **New Strategies for Dealing with *Staphylococcus aureus* Colonization and the Emerging Methicillin-Resistant *Staphylococcus aureus* Epidemic in Atopic Dermatitis**

Boguniewicz, M. (Denver, Colo.)

- 113 Abstract
- 113 Community-Acquired Methicillin-Resistant *Staphylococcus aureus*

114	Why Is Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> So Virulent?
115	<i>Staphylococcus aureus</i> , Toxins and Atopic Dermatitis
115	Strategies for Dealing with Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization in the Community Setting
116	Novel Approaches to Dealing with Resistant <i>Staphylococcus aureus</i>
117	Conclusions
118	References

120 Anti-IL-4 as a New Strategy in Allergy

Schmidt-Weber, C.B. (Munich)

120	Abstract
121	IL-4 Receptors and Cellular Targets
121	New Concepts and Targets
122	Potential Side Effects
122	Target of Anti-IL-4 Therapy
123	Conclusion
123	References

126 New Drug Targets in Atopic Dermatitis

Simon, D.; Simon, H.-U. (Bern)

126	Abstract
127	Targeting B Cells
128	Targeting T Cells
129	Targeting B and T Cell Products
129	Discussion
130	Acknowledgements
130	References

132 Latest Approaches to Treating Atopic Dermatitis

Paller, A.S. (Chicago, Ill.)

132	Abstract
133	Impairment of the Epidermal Barrier: Proteins, Proteases and Lipids
134	Translation of Discoveries about Barrier Dysfunction into New Therapy
135	The Importance of <i>Staphylococcus aureus</i> in Atopic Dermatitis
136	Improving Atopic Dermatitis through Decreasing Organisms
137	Topical Anti-inflammatory Therapy Continues to Be Critical as Treatment
138	The Recalcitrant Patient
138	Conclusions
139	References

141 Author Index

143 Subject Index